TCGA-33-4583-01A-01R-1443-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.640
- E2F_TARGETS+0.610
- OXIDATIVE_PHOSPHORYLATION+0.550
- MYC_TARGETS_V2+0.540
- MTORC1_SIGNALING+0.530
- G2M_CHECKPOINT+0.520
- INTERFERON_ALPHA_RESPONSE+0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
- PANCREAS_BETA_CELLS+0.330
- UV_RESPONSE_UP+0.330
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- ANGIOGENESIS-0.320
- NOTCH_SIGNALING-0.230
- UV_RESPONSE_DN-0.220
- MYOGENESIS-0.190
- WNT_BETA_CATENIN_SIGNALING-0.160
- COAGULATION-0.110
- KRAS_SIGNALING_UP-0.100
- APICAL_JUNCTION-0.090
- IL6_JAK_STAT3_SIGNALING-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579824 | — | E | 0.877 |
| 2 | TCGA-66-2794-01A-01R-1201-07 | — | cohortSQ2 | 0.868 |
| 3 | 17-020P2_Bladder | — | — | 0.863 |
| 4 | BS_J483EMFP | ATRT | — | 0.855 |
| 5 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.852 |
| 6 | SRR6013495 | — | cohortA1 | 0.851 |
| 7 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.850 |
| 8 | f6d998cd-20fa-4add-8fa7-6b89ff16f8bd | — | — | 0.846 |
| 9 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.845 |
| 10 | SRR11296765 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.640 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.610 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.450 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |